Thomas Strungmann Founder of Hexal AG Thomas Country: Germany

Content:

1. Biography of Thomas Strüngmann
2. Early Life and Education
3. Success in the Pharmaceutical Industry
4. Acquisition and Current Ventures
5. Contributions to Sandoz and Novartis
6. Commitment to Excellence

Biography of Thomas Strüngmann

Thomas Strüngmann, the co-founder of the pharmaceutical company "Hexal AG," is a renowned entrepreneur and billionaire. Alongside his twin brother, Andreas, they established Hexal AG in 1986, which has since become one of the most well-known pharmaceutical companies not only in Germany but also internationally.

Early Life and Education

Thomas Strüngmann obtained his higher education and an MBA degree from the University of Augsburg. With his strong academic background, he ventured into the field of pharmacology, dedicating his career to developing innovative and high-quality pharmaceutical products.

Success in the Pharmaceutical Industry

Under Thomas Strüngmann's leadership, Hexal AG flourished and gained significant recognition in the pharmaceutical market. The company's success attracted the attention of Forbes, which acknowledged Thomas and his brother Andreas as some of the wealthiest individuals in the world.

Acquisition and Current Ventures

In 2005, the Strüngmann brothers sold Hexal AG to the prominent pharmaceutical organization, Novartis, for approximately $7.5 billion. Presently, Thomas and Andreas serve as executive directors of Sandoz, a subsidiary of Novartis.

Contributions to Sandoz and Novartis

Sandoz, under the guidance of Thomas Strüngmann, has become one of the largest pharmaceutical manufacturers in the United States. The company produces over 200 products and employs more than 1,500 staff members. Sandoz's affiliation with Novartis AG, a recognized global leader in healthcare, further enhances its position in the industry.

Commitment to Excellence

Thomas and Andreas Strüngmann take great pride in their work, demonstrating exceptional control over the production and distribution of competitive and high-quality pharmaceutical products. Their focus lies in developing medications for cardiovascular and gastrointestinal diseases, as well as various other ailments.

In conclusion, Thomas Strüngmann's dedication to the pharmaceutical industry has propelled his success as an entrepreneur and billionaire. His contributions to Hexal AG and Sandoz have solidified his position as a prominent figure in the global pharmaceutical market.

Pharmaceuticals

Otto Loewi	Henry McKinnell	Corneille Heymans
Habil Khorakiwala	James Kew	Jeffrey Kindler